Citius Oncology
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell CTOR and other ETFs, options, and stocks.About CTOR
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.
CEOLeonard L. Mazur
CEOLeonard L. Mazur
Employees—
Employees—
HeadquartersCranford, New Jersey
HeadquartersCranford, New Jersey
Founded2021
Founded2021
Employees—
Employees—
CTOR Key Statistics
Market cap93.54M
Market cap93.54M
Price-Earnings ratio-5.83
Price-Earnings ratio-5.83
Dividend yield—
Dividend yield—
Average volume1.06M
Average volume1.06M
High today$1.47
High today$1.47
Low today$1.02
Low today$1.02
Open price$1.16
Open price$1.16
Volume2.12M
Volume2.12M
52 Week high$6.19
52 Week high$6.19
52 Week low$0.5506
52 Week low$0.5506
Stock Snapshot
As of today, Citius Oncology(CTOR) shares are valued at $1.12. The company's market cap stands at 93.54M, with a P/E ratio of -5.83.
On 2025-12-04, Citius Oncology(CTOR) stock traded between a low of $1.02 and a high of $1.47. Shares are currently priced at $1.12, which is +9.7% above the low and -23.9% below the high.
The Citius Oncology(CTOR)'s current trading volume is 2.12M, compared to an average daily volume of 1.06M.
During the past year, Citius Oncology(CTOR) stock moved between $0.55 at its lowest and $6.19 at its peak.
During the past year, Citius Oncology(CTOR) stock moved between $0.55 at its lowest and $6.19 at its peak.
People also own
Based on the portfolios of people who own CTOR. This list is generated using Robinhood data, and it’s not a recommendation.